233 related articles for article (PubMed ID: 29413686)
1. Determinants and prognostic value of quality of life in patients with pancreatic ductal adenocarcinoma.
Deng Y; Tu H; Pierzynski JA; Miller ED; Gu X; Huang M; Chang DW; Ye Y; Hildebrandt MAT; Klein AP; Zhao R; Lippman SM; Wu X
Eur J Cancer; 2018 Mar; 92():20-32. PubMed ID: 29413686
[TBL] [Abstract][Full Text] [Related]
2. Association of Treatment Inequity and Ancestry With Pancreatic Ductal Adenocarcinoma Survival.
Heller DR; Nicolson NG; Ahuja N; Khan S; Kunstman JW
JAMA Surg; 2020 Feb; 155(2):e195047. PubMed ID: 31800002
[TBL] [Abstract][Full Text] [Related]
3. Disparities in Pancreatic Ductal Adenocarcinoma-The Significance of Hispanic Ethnicity, Subgroup Analysis, and Treatment Facility on Clinical Outcomes.
Riner AN; Underwood PW; Yang K; Herremans KM; Cameron ME; Chamala S; Qiu P; George TJ; Permuth JB; Merchant NB; Trevino JG
Cancer Med; 2020 Jun; 9(12):4069-4082. PubMed ID: 32285629
[TBL] [Abstract][Full Text] [Related]
4. Metformin Use and Pancreatic Cancer Survival among Non-Hispanic White and African American U.S. Veterans with Diabetes Mellitus.
Toriola AT; Luo S; Thomas TS; Drake BF; Chang SH; Sanfilippo KM; Carson KR
Cancer Epidemiol Biomarkers Prev; 2020 Jan; 29(1):169-175. PubMed ID: 31685560
[TBL] [Abstract][Full Text] [Related]
5. ABO blood type, smoking status, other risk factors and prognosis of pancreatic ductal adenocarcinoma.
Li SS; Zhou CY; Liao R; Xiong L; Weng NN; Zhao YQ; Mason C; Gou HF; Yi C; Zhu Q
Medicine (Baltimore); 2020 Apr; 99(14):e19413. PubMed ID: 32243360
[TBL] [Abstract][Full Text] [Related]
6. Quality of life in patients with pancreatic ductal adenocarcinoma undergoing pancreaticoduodenectomy.
Laitinen I; Sand J; Peromaa P; Nordback I; Laukkarinen J
Pancreatology; 2017; 17(3):445-450. PubMed ID: 28274687
[TBL] [Abstract][Full Text] [Related]
7. Longitudinal health-related quality of life assessment implications for prognosis in stage IV pancreatic cancer.
Braun DP; Gupta D; Staren ED
Pancreas; 2013 Mar; 42(2):254-9. PubMed ID: 22850626
[TBL] [Abstract][Full Text] [Related]
8. Linc00675 is a novel marker of short survival and recurrence in patients with pancreatic ductal adenocarcinoma.
Li DD; Fu ZQ; Lin Q; Zhou Y; Zhou QB; Li ZH; Tan LP; Chen RF; Liu YM
World J Gastroenterol; 2015 Aug; 21(31):9348-57. PubMed ID: 26309360
[TBL] [Abstract][Full Text] [Related]
9. Increased neutrophil-to-lymphocyte ratio after neoadjuvant therapy is associated with worse survival after resection of borderline resectable pancreatic ductal adenocarcinoma.
Glazer ES; Rashid OM; Pimiento JM; Hodul PJ; Malafa MP
Surgery; 2016 Nov; 160(5):1288-1293. PubMed ID: 27450715
[TBL] [Abstract][Full Text] [Related]
10. Is chronic hepatitis B infection a protective factor for the progression of advanced pancreatic ductal adenocarcinoma? An analysis from a large multicenter cohort study.
Chen Q; Ning Z; Wang L; Ying H; Dong S; Zhang C; Shen X; Guo Y; Chen H; Zhu X; Shen Y; Shi W; Hua Y; Wang K; Lin J; Xu L; Chen L; Feng L; Zhang X; Xie J; Sun B; Sun Y; Gu W; Kang M; Tang Z; Chen Z; Chen Z; Liu L; Yu J; Li Z; Meng Z
Oncotarget; 2016 Dec; 7(51):85603-85612. PubMed ID: 27811354
[TBL] [Abstract][Full Text] [Related]
11. Association of Glycated Hemoglobin Levels With Risk of Pancreatic Cancer.
Wu BU; Butler RK; Lustigova E; Lawrence JM; Chen W
JAMA Netw Open; 2020 Jun; 3(6):e204945. PubMed ID: 32530471
[TBL] [Abstract][Full Text] [Related]
12. Elevated systemic inflammatory responses, factors associated with physical and mental quality of life, and prognosis of hepatocellular carcinoma.
Deng Y; Zhu J; Liu Z; Huang M; Chang DW; Gu J
Aging (Albany NY); 2020 Mar; 12(5):4357-4370. PubMed ID: 32145060
[TBL] [Abstract][Full Text] [Related]
13. Preoperative cognitive function predicts survival in patients with resectable pancreatic ductal adenocarcinoma.
Baekelandt BM; Hjermstad MJ; Nordby T; Fagerland MW; Kure EH; Heiberg T; Buanes T; Labori KJ
HPB (Oxford); 2016 Mar; 18(3):247-54. PubMed ID: 27017164
[TBL] [Abstract][Full Text] [Related]
14. Noteworthy prognostic value of phospholipase C delta genes in early stage pancreatic ductal adenocarcinoma patients after pancreaticoduodenectomy and potential molecular mechanisms.
Zhou X; Liao X; Wang X; Huang K; Yang C; Yu T; Han C; Zhu G; Su H; Han Q; Chen Z; Huang J; Gong Y; Ruan G; Ye X; Peng T
Cancer Med; 2020 Feb; 9(3):859-871. PubMed ID: 31808619
[TBL] [Abstract][Full Text] [Related]
15. Risk of pancreatic adenocarcinoma: disparity between African Americans and other race/ethnic groups.
Chang KJ; Parasher G; Christie C; Largent J; Anton-Culver H
Cancer; 2005 Jan; 103(2):349-57. PubMed ID: 15593353
[TBL] [Abstract][Full Text] [Related]
16. Serum osteopontin and tissue inhibitor of metalloproteinase 1 as diagnostic and prognostic biomarkers for pancreatic adenocarcinoma.
Poruk KE; Firpo MA; Scaife CL; Adler DG; Emerson LL; Boucher KM; Mulvihill SJ
Pancreas; 2013 Mar; 42(2):193-7. PubMed ID: 23407481
[TBL] [Abstract][Full Text] [Related]
17. Reduced mean platelet volume levels predict shorter survival in patients with resectable pancreatic ductal adenocarcinoma and type 2 diabetes.
Yin JB; Li N; Cui MM; Wang X; Wang RT
BMC Gastroenterol; 2020 May; 20(1):143. PubMed ID: 32393273
[TBL] [Abstract][Full Text] [Related]
18. PROX1 and β-catenin are prognostic markers in pancreatic ductal adenocarcinoma.
Saukkonen K; Hagström J; Mustonen H; Juuti A; Nordling S; Kallio P; Alitalo K; Seppänen H; Haglund C
BMC Cancer; 2016 Jul; 16():472. PubMed ID: 27411302
[TBL] [Abstract][Full Text] [Related]
19. The impact of neoadjuvant and adjuvant immunotherapy on the survival of pancreatic cancer patients: a retrospective analysis.
Amin S; Baine M; Meza J; Lin C
BMC Cancer; 2020 Jun; 20(1):538. PubMed ID: 32517661
[TBL] [Abstract][Full Text] [Related]
20. Racial disparities in treatment for pancreatic cancer and impact on survival: a population-based analysis.
Singal V; Singal AK; Kuo YF
J Cancer Res Clin Oncol; 2012 Apr; 138(4):715-22. PubMed ID: 22246279
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
